GlassScriptPhysician profile
David A Seidl
NPI 1578509527
$13,609.23
in general payments reported to CMS, 2019-2025
19 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,026 · 2020: $4,858 · 2021: $816 · 2022: $957 · 2023: $1,603 · 2024: $1,283 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,952.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,680.78 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,874.59 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $715.15 | 2019-2025 | |
| Celgene Corporation | $347.37 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $284.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $279.94 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $255.25 | 2019-2025 | Eohilia, Gattex |
| Janssen Biotech, INC. | $224.16 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $211.39 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $198.14 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $147.68 | 2024 | Omvoh |
| Genentech USA, INC. | $94.78 | 2019 | |
| Ambu INC. | $91.15 | 2021 | |
| Pfizer INC. | $83.24 | 2019 | |
| Welch Allyn | $34.99 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $34.99 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.68 | 2023 | Dupixent |
| Boston Scientific Corporation | $14.04 | 2021 | |
| Braintree Laboratories, INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Seidl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.